CASI Pharmeceuticals

MARQIBO

Marqibo

Marqibo® is a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor. Marqibo is approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Please see Marqibo product and safety information.

Since MARQIBO is already approved in the U.S. and marketed by our licensor, we expect that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs. We submitted an import drug registration is pending with CFDA.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →